4 news items
Acorda Therapeutics Announces Delisting from Nasdaq
ACORQ
15 Apr 24
of unfavorable results from future studies of INBRIJA (levodopa inhalation powder) or from other research and development programs, or any other acquired
Acorda Therapeutics Announces Nasdaq Delisting Notification
ACORQ
3 Apr 24
inhalation powder) or from other research and development programs, or any other acquired or in-licensed programs; the occurrence of adverse safety
Acorda Therapeutics and Merz Announce Signing of "Stalking Horse" Asset Purchase Agreement
ACORQ
1 Apr 24
powder) or from other research and development programs, or any other acquired or in-licensed programs; the occurrence of adverse safety events
Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024
ACORQ
1 Apr 24
of unfavorable results from future studies of INBRIJA (levodopa inhalation powder) or from other research and development programs, or any other acquired
- Prev
- 1
- Next